Boston Oncology Arabia and SPIMACO forge partnership to localize cancer treatments in Saudi Arabia

In a move set to transform oncology care in the Middle East, Boston Oncology Arabia and Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO) have signed a landmark Memorandum of Understanding (MoU). This collaboration, unveiled at the CPHI Middle East conference, aims to localize the production of advanced oral oncology treatments within Saudi Arabia. The partnership reflects a commitment to addressing critical healthcare needs while supporting the Kingdom’s Vision 2030 objectives of healthcare innovation and industrial self-reliance.

A Milestone In Cancer Care Localization

The agreement focuses on technology transfer and local manufacturing to produce essential oral oncology medications. By prioritizing domestic production, the initiative aims to make life-saving treatments more accessible to patients in Saudi Arabia and the broader GCC region. Industry experts highlight this as a crucial step in reducing reliance on imported pharmaceuticals, ensuring timely access to cutting-edge treatments, and strengthening local infrastructure.

Dr. Abdullah Baaj, CEO of Boston Oncology Arabia, underscored the importance of the partnership. He described the initiative as a model for sustainable oncology care in the Middle East, combining advanced technology and local expertise to meet immediate healthcare needs while paving the way for long-term innovation.

SPIMACO’s CEO, Jérôme Cabannes, added that the collaboration enhances the Kingdom’s capacity to meet growing healthcare demands. He emphasized its alignment with Saudi Arabia’s goals of fostering a self-sufficient healthcare system and advancing patient outcomes.

Advancing Saudi Arabia’s Vision 2030

The partnership supports Saudi Arabia’s Vision 2030, which emphasizes reducing dependency on imports, promoting local manufacturing, and enhancing the accessibility of innovative healthcare solutions. By establishing local production capabilities for oral oncology treatments, the initiative strengthens the Kingdom’s position as a leader in the regional pharmaceutical industry.

This collaboration also promises to create significant socio-economic benefits, including job creation, skill development, and the establishment of advanced production facilities. Over the next five years, Boston Oncology Arabia and SPIMACO aim to commercialize key oncology therapies, providing equitable access to critical treatments across Saudi Arabia and the MENA region.

Transforming The Oncology Landscape

Experts view the collaboration as a turning point for the regional healthcare industry, particularly in oncology. By leveraging cutting-edge technology and fostering strategic partnerships, Saudi Arabia is setting a precedent for addressing unmet healthcare needs in a sustainable and scalable way. The localization of oncology drug production is expected to inspire similar initiatives across the region, further advancing cancer care accessibility.

About Boston Oncology Arabia

Headquartered in Riyadh, Boston Oncology Arabia is a leading pharmaceutical company with a mission to improve the lives of one billion patients by 2030. The company specializes in licensing, local development, and the production of world-class medications. Its innovative approach to supply chain management ensures that essential therapies reach healthcare providers efficiently and affordably, making transformative treatments accessible to patients across the region.